Bactericidal éfficacy of molybdenum oxide nanoparticles against antimicrobial-resistant pathogens

E. Lopes, S. Piçarra, P. L. Almeida, H. de Lencastre, M. Aires-De-Sousa

Research output: Contribution to journalArticle

10 Citations (Scopus)


Multidrug-resistant bacteria pose a major threat to effective antibiotics and alternatives to fight multidrug-resistant pathogens are needed. We synthetized molybdenum oxide (MoO3) nanoparticles (NP) and determined their antibacterial activity against 39 isolates: (i) eight Staphylococcus aureus, including representatives of methicillin-resistant S. aureus epidemic clones; (ii) six enterococci, including vancomycin-resistant isolates; and (iii) 25 Gram-negative isolates (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacter cloacae), including extended spectrum beta-lactamases and carbapenemases producers. All isolates showed a MoO3 NP MIC of 700–800 mgl-1. MoO3 NP produced a clear inhibition zone for S. aureus and all Gram-negative isolates at concentrations ≥25mg ml-1 and ≥50 mgml-1 for enterococci. When the NP solutions were adjusted to pH ~7, the biocidal activity was completely abolished. MoO3 NP create an acidic pH and show a universal antimicrobial activity against susceptible and resistant isolates belonging to the most relevant bacterial species responsible for hospital-acquired infections.

Original languageEnglish
Article number000789
Pages (from-to)1042-1046
Number of pages5
JournalJournal of Medical Microbiology
Issue number8
Publication statusPublished - 1 Aug 2018


  • Bactericidal efficacy
  • Molybdenum oxide
  • Multidrug-resistant bacteria
  • Nanoparticles

Fingerprint Dive into the research topics of 'Bactericidal éfficacy of molybdenum oxide nanoparticles against antimicrobial-resistant pathogens'. Together they form a unique fingerprint.

Cite this